 |
|
Bupropion in DepressionII. The Role of Metabolites in Clinical Outcome
Robert N. Golden, MD;
C. Lindsay DeVane, PharmD;
S. Casey Laizure, PharmD;
Matthew V. Rudorfer, MD;
Michael A. Sherer, MD;
William Z. Potter, MD, PhD
Arch Gen Psychiatry. 1988;45(2):145-149.
Abstract
• We studied the steady-state pharmacokinetics of bupropion hydrochloride, a unicyclic aminoketone antidepressant, in depressed patients. The metabolites hydroxybupropion (HB), threohydrobupropion, and erythrohydrobupropion predominated over the parent compound in plasma and cerebrospinal fluid at steady state. Plasma concentrations of each metabolite correlated with cerebrospinal fluid concentrations. Higher plasma metabolite concentrations were associated with poor clinical outcome. This relationship was most striking with HB; plasma HB levels were greater than 1250 ng/mL in all five nonresponders and less than 1200 ng/mL in all seven responders. Plasma HB levels correlated with postreatment plasma homovanillic acid levels. High levels of bupropion metabolites may be associated with poor clinical outcome due to toxic effects involving dopaminergic systems. Alternatively, a curvilinear dose-response relationship may exist for bupropion metabolites. Future studies should explore the clinical utility of plasma metabolite measurements in enhancing the efficacy of treatment with bupropion.
Author Affiliations
From the Section on Clinical Pharmacology, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Md (Drs Golden, Rudorfer, Sherer, and Potter); and the Department of Pharmacy Practice, College of Pharmacy (Drs DeVane and Laizure) and the Department of Psychiatry, College of Medicine (Dr DeVane), University of Florida, Gainesville. Dr Golden is now with the University of North Carolina School of Medicine, Chapel Hill.
Footnotes
Accepted for publication Aug 19, 1985.
Read in part at the 40th annual meeting of the Society of Biological Psychiatry, Dallas, May 17, 1985; and at the 138th annual meeting of the American Psychiatric Association, Dallas, May 22, 1985.
Reprint requests to Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27514 (Dr Golden).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effects of Menthol on the Pharmacokinetics of Bupropion Among Black Smokers
Okuyemi et al.
Nicotine Tob Res 2012;0:ntr268v1-ntr268.
ABSTRACT
| FULL TEXT
Effects of Hydroxymetabolites of Bupropion on Nicotine Dependence Behavior in Mice
Damaj et al.
J. Pharmacol. Exp. Ther. 2010;334:1087-1095.
ABSTRACT
| FULL TEXT
An in Vitro Mechanistic Study to Elucidate the Desipramine/Bupropion Clinical Drug-Drug Interaction
Reese et al.
Drug Metab. Dispos. 2008;36:1198-1201.
ABSTRACT
| FULL TEXT
Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers.
Hesse et al.
J Clin Pharmacol 2006;46:567-576.
ABSTRACT
| FULL TEXT
THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATION
Bumpus et al.
Drug Metab. Dispos. 2005;33:795-802.
ABSTRACT
| FULL TEXT
Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic Receptors
Damaj et al.
Mol. Pharmacol. 2004;66:675-682.
ABSTRACT
| FULL TEXT
Evaluation of the Contribution of Cytochrome P450 3A4 to Human Liver Microsomal Bupropion Hydroxylation
Faucette et al.
Drug Metab. Dispos. 2001;29:1123-1129.
ABSTRACT
| FULL TEXT
CYP2B6 Mediates the In Vitro Hydroxylation of Bupropion: Potential Drug Interactions with Other Antidepressants
Hesse et al.
Drug Metab. Dispos. 2000;28:1176-1183.
ABSTRACT
| FULL TEXT
Noncompetitive Functional Inhibition at Diverse, Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine
Fryer and Lukas
J. Pharmacol. Exp. Ther. 1999;288:88-92.
ABSTRACT
| FULL TEXT
Standards of laboratory practice: antidepressant drug monitoring
Linder and Keck
Clin. Chem. 1998;44:1073-1084.
ABSTRACT
| FULL TEXT
Bupropion in Depression: I. Biochemical Effects and Clinical Response
Golden et al.
Arch Gen Psychiatry 1988;45:139-143.
ABSTRACT
Antidepressants Reduce Whole-Body Norepinephrine Turnover While Enhancing 6-Hydroxymelatonin Output
Golden et al.
Arch Gen Psychiatry 1988;45:150-154.
ABSTRACT
Where Are Those New Antidepressants We Were Promised?
Cole
Arch Gen Psychiatry 1988;45:193-194.
ABSTRACT
|
